文献速递脑血管病

多病共存与卒中严重程度、亚型、病前残疾及早期死亡率的关联:牛津血管研究

Associations of Multimorbidity With Stroke Severity, Subtype, Premorbid Disability, and Early Mortality: Oxford Vascular Study.
PubMed 文献 · Neurology · 2023-06-15

基于牛津血管研究2002-2017年2492例首发卒中患者,分析多病共存(查尔森共病指数)与卒中后严重程度、亚型、病前残疾及90天死亡率的关联。多病共存与病前残疾强相关(aOR 1.42),与缺血性卒中严重程度无独立关联(按TOAST分层后aOR 1.02和0.99),与90天死亡率仅弱相关(aHR 1.09)。

要点

  • 按TOAST亚型分层后,多病共存与缺血性卒中严重程度无独立关联。

核心结论

  • 多病共存与病前残疾强相关,但与缺血性卒中严重程度无独立关联,与90天死亡率仅弱相关。
  • 作者认为,临床试验更多纳入多病共存患者不太可能削弱干预效果,但会增加外部有效性。

研究设计与样本

  • 基于人群的发病率研究(牛津血管研究,2002-2017年),纳入2492例首次卒中患者。
  • 平均年龄74.5岁(SD 13.9),男性1216例(48.8%),缺血性卒中2160例(86.7%),平均NIHSS 5.7(SD 7.1)。
  • 采用年龄和性别调整的logistic回归与线性回归模型分析卒中后严重程度、亚型和病前残疾,采用Cox比例风险模型分析90天死亡率。

主要发现

  • 1402例(56.2%)至少有1种CCI共病,700例(28.1%)有多病共存。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Patients with multimorbidity are underrepresented in clinical trials. Inclusion in stroke trials is often limited by exclusion based on premorbid disability, concerns about worse poststroke outcomes in acute treatment trials, and a possibly increased proportion of hemorrhagic vs ischemic stroke in prevention trials. Multimorbidity is associated with an increased mortality after stroke, but it is unclear whether this is driven by an increased stroke severity or is confounded by particular stroke subtypes or premorbid disability. We aimed to determine the independent association of multimorbidity with stroke severity taking account of these main potential confounders. METHODS: In a population-based incidence study (Oxford Vascular Study; 2002-2017), prestroke multimorbidity (Charlson Comorbidity Index [CCI]; unweighted/weighted) in all first-in-study strokes was related to postacute severity (≈24 hours; NIH Stroke Scale [NIHSS]), stroke subtype (hemorrhagic vs ischemic; Trial of Org 10172 in Acute Stroke Treatment [TOAST]), and premorbid disability (modified Rankin scale [mRS] score ≥2) using age-adjusted/sex-adjusted logistic and linear regression models and to 90-day mortality using Cox proportional hazard models. RESULTS: Among 2,492 patients (mean/SD age = 74.5/13.9 years; 1,216/48.8% male; 2,160/86.7% ischemic strokes; mean/SD NIHSS = 5.7/7.1), 1,402 (56.2%) had at least 1 CCI comorbidity, and 700 (28.1%) had multimorbidity. Although multimorbidity was strongly related to premorbid mRS ≥2 (adjusted odds ratio [aOR] per CCI comorbidity 1.42, 1.31-1.54, p < 0.001), and comorbidity burden was crudely associated with an increased severity of ischemic stroke (OR per comorbidity 1.12, 1.01-1.23 for NIHSS 5-9, p = 0.027; 1.15, 1.06-1.26 for NIHSS ≥10; p = 0.001), no association with severity remained after stratification by TOAST subtype (aOR 1.02, 0.90-1.14, p = 0.78 for NIHSS 5-9 vs 0-4; 0.99, 0.91-1.07, p = 0.75 for NIHSS ≥10 vs 0-4), or within any individual subtype. The proportion of intracerebral hemorrhage vs ischemic stroke was lower in patients with multimorbidity (aOR per comorbidity 0.80, 0.70-0.92, p < 0.001), and multimorbidity was only weakly associated with 90-day mortality after adjustment for age, sex, severity, and premorbid disability (adjusted hazard ratio per comorbidity 1.09, 1.04-1.14, p < 0.001). Results were unchanged using the weighted CCI. DISCUSSION: Multimorbidity is common in patients with stroke and is strongly related to premorbid disability but is not independently associated with an increased ischemic stroke severity. Greater inclusion of patients with multimorbidity is unlikely therefore to undermine the effectiveness of interventions in clinical trials but would increase external validity.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Downer MB, Li L, Carter S, et al. Associations of Multimorbidity With Stroke Severity, Subtype, Premorbid Disability, and Early Mortality: Oxford Vascular Study. Neurology. 2023. PMID: 37321865. doi:10.1212/WNL.0000000000207479

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。